- Home
- HOOK vs FLUX Comparison
HOOK vs FLUX Comparison
Compare HOOK & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- FLUX
- Stock Information
- Founded
- HOOK 2011
- FLUX N/A
- Country
- HOOK United States
- FLUX United States
- Employees
- HOOK N/A
- FLUX N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- FLUX Industrial Machinery/Components
- Sector
- HOOK Health Care
- FLUX Miscellaneous
- Exchange
- HOOK Nasdaq
- FLUX Nasdaq
- Market Cap
- HOOK 9.3M
- FLUX 20.2M
- IPO Year
- HOOK 2019
- FLUX N/A
- Fundamental
- Price
- HOOK $1.47
- FLUX $1.97
- Analyst Decision
- HOOK Buy
- FLUX Strong Buy
- Analyst Count
- HOOK 4
- FLUX 3
- Target Price
- HOOK $10.67
- FLUX $6.33
- AVG Volume (30 Days)
- HOOK 134.3K
- FLUX 30.3K
- Earning Date
- HOOK 05-20-2025
- FLUX 05-08-2025
- Dividend Yield
- HOOK N/A
- FLUX N/A
- EPS Growth
- HOOK N/A
- FLUX N/A
- EPS
- HOOK N/A
- FLUX N/A
- Revenue
- HOOK $43,946,000.00
- FLUX $60,789,000.00
- Revenue This Year
- HOOK N/A
- FLUX $11.85
- Revenue Next Year
- HOOK N/A
- FLUX $13.10
- P/E Ratio
- HOOK N/A
- FLUX N/A
- Revenue Growth
- HOOK 118.32
- FLUX N/A
- 52 Week Low
- HOOK $0.72
- FLUX $1.15
- 52 Week High
- HOOK $10.50
- FLUX $4.98
- Technical
- Relative Strength Index (RSI)
- HOOK 67.61
- FLUX 67.05
- Support Level
- HOOK $1.14
- FLUX $1.67
- Resistance Level
- HOOK $1.67
- FLUX $1.88
- Average True Range (ATR)
- HOOK 0.16
- FLUX 0.15
- MACD
- HOOK 0.10
- FLUX 0.04
- Stochastic Oscillator
- HOOK 78.69
- FLUX 99.04
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.